Aptose Biosciences (NASDAQ:APTO – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
Profitability
This table compares Aptose Biosciences and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aptose Biosciences | N/A | -5,683.22% | -300.44% |
| Monte Rosa Therapeutics | N/A | -62.68% | -38.83% |
Earnings and Valuation
This table compares Aptose Biosciences and Monte Rosa Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aptose Biosciences | N/A | N/A | -$51.21 million | ($89.19) | N/A |
| Monte Rosa Therapeutics | $159.49 million | 1.53 | -$135.35 million | $0.08 | 49.63 |
Aptose Biosciences has higher earnings, but lower revenue than Monte Rosa Therapeutics. Aptose Biosciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations for Aptose Biosciences and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aptose Biosciences | 0 | 0 | 1 | 1 | 3.50 |
| Monte Rosa Therapeutics | 0 | 1 | 3 | 0 | 2.75 |
Aptose Biosciences presently has a consensus price target of $6.00, suggesting a potential upside of 0.00%. Monte Rosa Therapeutics has a consensus price target of $15.50, suggesting a potential upside of 290.43%. Given Monte Rosa Therapeutics’ higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Aptose Biosciences.
Institutional and Insider Ownership
26.6% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 1.3% of Aptose Biosciences shares are owned by insiders. Comparatively, 6.9% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Aptose Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
Summary
Monte Rosa Therapeutics beats Aptose Biosciences on 9 of the 13 factors compared between the two stocks.
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
